Tuyển tập các báo cáo nghiên cứu khoa học ngành y học tạp chí Medical Sciences dành cho các bạn sinh viên ngành y tham khảo đề tài: Adverse Event Profiles of Platinum Agents: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations. | Int. J. Med. Sci. 2011 8 487 o IVYSPRING . . I fl. International Journal of Medical Sciences 2011 8 6 487-491 Research Paper Adverse Event Profiles of Platinum Agents Data Mining of the Public Version of the FDA Adverse Event Reporting System AERS and Reproducibility of Clinical Observations Toshiyuki Sakaeda 1X Kaori Kadoyama 1 and Yasushi Okuno 2 3X 1. Center for Integrative Education in Pharmacy and Pharmaceutical Sciences Graduate School of Pharmaceutical Sciences Kyoto University Kyoto 606-8501 Japan 2. Department of Systems Biosciences for Drug Discovery Graduate School of Pharmaceutical Sciences Kyoto University Kyoto 606-8501 Japan 3. Kyoto Constella Technologies Co. Ltd. Kyoto 604-8156 Japan H Corresponding author Toshiyuki Sakaeda . Center for Integrative Education in Pharmacy and Pharmaceutical Sciences Graduate School of Pharmaceutical Sciences Kyoto University Kyoto 606-8501 Japan Tel 81-75-753-9560 Fax 81-75-753-9253 e-mail sakaedat@ Yasushi Okuno . Department of Systems Biosciences for Drug Discovery Graduate School of Pharmaceutical Sciences Kyoto University Kyoto 606-8501 Japan Tel Fax 81-75-753-4559 e-mail okuno@ Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License http licenses by-nc-nd . Reproduction is permitted for personal noncommercial use provided that the article is in whole unmodified and properly cited. Received Accepted Published Abstract Objective Adverse event reports AERs submitted to the US Food and Drug Administration FDA were reviewed to confirm platinum agent-associated adverse events and to clarify the rank-order of these drugs in terms of susceptibility. Methods After a revision of arbitrary drug names and the deletion of duplicated submissions AERs involving cisplatin CDDP carboplatin CBDCA or oxaliplatin L-OHP were analyzed. Authorized pharmacovigilance
